Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case ReportNovel Teaching Points
This report describes an episode of severe hypoglycemia in a 55-year-old woman with type 1 diabetes mellitus approximately 2 weeks after initiating sacubitril/valsartan for heart failure. She was receiving a continuous subcutaneous insulin infusion and denied any severe hypoglycemic events in the pr...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-05-01
|
Series: | CJC Open |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589790X20300135 |
id |
doaj-91f8a435f38449a1a227c346f12aa73a |
---|---|
record_format |
Article |
spelling |
doaj-91f8a435f38449a1a227c346f12aa73a2020-11-25T02:34:28ZengElsevierCJC Open2589-790X2020-05-0123176178Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case ReportNovel Teaching PointsArden R. Barry, BSc, BSc(Pharm), PharmD, ACPR0Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Heart Function Clinic, Abbotsford Regional Hospital and Cancer Centre, Lower Mainland Pharmacy Services, Abbotsford, British Columbia, Canada; Corresponding author: Dr Arden R. Barry, Faculty of Pharmaceutical Sciences, 2405 Wesbrook Mall, Vancouver, British Columbia, V6T 1Z3, Canada. Tel.: +1-604-897-2439; fax: +1-604-822-3035.This report describes an episode of severe hypoglycemia in a 55-year-old woman with type 1 diabetes mellitus approximately 2 weeks after initiating sacubitril/valsartan for heart failure. She was receiving a continuous subcutaneous insulin infusion and denied any severe hypoglycemic events in the prior 13 years. She experienced a second hypoglycemic episode 1 week later. She subsequently reduced her insulin dose and continued on sacubitril/valsartan. Eight months later, she did not have any recurrent hypoglycemic episodes. Clinicians should be aware of this potential adverse effect and educate patients on concomitant insulin therapy to monitor for symptoms of hypoglycemia when initiating sacubitril/valsartan. Résumé: Les auteurs présentent le cas d’une femme de 55 ans atteinte de diabète de type 1 qui a subi un épisode d’hypoglycémie sévère environ deux semaines après la mise en route d’un traitement de l’insuffisance cardiaque par l’association sacubitril-valsartan. La patiente recevait alors de l’insuline par perfusion sous-cutanée continue et avait affirmé n’avoir subi aucun épisode d’hypoglycémie sévère depuis 13 ans. Un deuxième épisode d’hypoglycémie est survenu une semaine après le premier. La patiente a par la suite réduit sa dose d’insuline et poursuivi le traitement par l’association sacubitril-valsartan. Huit mois plus tard, elle n’avait subi aucun autre épisode d’hypoglycémie. Il importe que les cliniciens soient au fait de cet effet indésirable possible et qu’ils avisent leurs patients sous insulinothérapie concomitante de surveiller les symptômes d’hypoglycémie à la mise en route d’un traitement par l’association sacubitril-valsartan.http://www.sciencedirect.com/science/article/pii/S2589790X20300135 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Arden R. Barry, BSc, BSc(Pharm), PharmD, ACPR |
spellingShingle |
Arden R. Barry, BSc, BSc(Pharm), PharmD, ACPR Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case ReportNovel Teaching Points CJC Open |
author_facet |
Arden R. Barry, BSc, BSc(Pharm), PharmD, ACPR |
author_sort |
Arden R. Barry, BSc, BSc(Pharm), PharmD, ACPR |
title |
Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case ReportNovel Teaching Points |
title_short |
Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case ReportNovel Teaching Points |
title_full |
Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case ReportNovel Teaching Points |
title_fullStr |
Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case ReportNovel Teaching Points |
title_full_unstemmed |
Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case ReportNovel Teaching Points |
title_sort |
severe hypoglycemia in a patient with type 1 diabetes mellitus recently started on sacubitril/valsartan: a case reportnovel teaching points |
publisher |
Elsevier |
series |
CJC Open |
issn |
2589-790X |
publishDate |
2020-05-01 |
description |
This report describes an episode of severe hypoglycemia in a 55-year-old woman with type 1 diabetes mellitus approximately 2 weeks after initiating sacubitril/valsartan for heart failure. She was receiving a continuous subcutaneous insulin infusion and denied any severe hypoglycemic events in the prior 13 years. She experienced a second hypoglycemic episode 1 week later. She subsequently reduced her insulin dose and continued on sacubitril/valsartan. Eight months later, she did not have any recurrent hypoglycemic episodes. Clinicians should be aware of this potential adverse effect and educate patients on concomitant insulin therapy to monitor for symptoms of hypoglycemia when initiating sacubitril/valsartan. Résumé: Les auteurs présentent le cas d’une femme de 55 ans atteinte de diabète de type 1 qui a subi un épisode d’hypoglycémie sévère environ deux semaines après la mise en route d’un traitement de l’insuffisance cardiaque par l’association sacubitril-valsartan. La patiente recevait alors de l’insuline par perfusion sous-cutanée continue et avait affirmé n’avoir subi aucun épisode d’hypoglycémie sévère depuis 13 ans. Un deuxième épisode d’hypoglycémie est survenu une semaine après le premier. La patiente a par la suite réduit sa dose d’insuline et poursuivi le traitement par l’association sacubitril-valsartan. Huit mois plus tard, elle n’avait subi aucun autre épisode d’hypoglycémie. Il importe que les cliniciens soient au fait de cet effet indésirable possible et qu’ils avisent leurs patients sous insulinothérapie concomitante de surveiller les symptômes d’hypoglycémie à la mise en route d’un traitement par l’association sacubitril-valsartan. |
url |
http://www.sciencedirect.com/science/article/pii/S2589790X20300135 |
work_keys_str_mv |
AT ardenrbarrybscbscpharmpharmdacpr severehypoglycemiainapatientwithtype1diabetesmellitusrecentlystartedonsacubitrilvalsartanacasereportnovelteachingpoints |
_version_ |
1724808635646738432 |